CAS NO: | 108341-18-0 |
包装 | 价格(元) |
500mg | 电议 |
1 g | 电议 |
5 g | 电议 |
10 g | 电议 |
50 g | 电议 |
生物活性 | Norepinephrine (Levarterenol; L-Noradrenaline) bitartrate monohydrate is a potentadrenergic receptor(AR)agonist. Norepinephrine activates α1, α2, β1receptors[1][2][3][4]. | ||||||||||||||||
IC50& Target[1][2] |
| ||||||||||||||||
体外研究 (In Vitro) | Norepinephrine (Levarterenol; L-Noradrenaline) bitartrate monohydrate is generally considered to be a β1-subtype selective adrenergic agonist over β2-adrenoceptor. Norepinephrine(NE) bitartrate monohydrate also has direct activity at the β2-adrenoceptor in higher concentrations[2].Adipocytes from the inguinal fat pad (iWA) or the interscapular fat pad (BA) are isolated from neonatal wild-type C57BL/6J mice and cultured. To examine the effect of activating AT2 upon β-adrenergic signaling, cAMP production is first assessed in response to Norepinephrine (NE, 10 μM) with or without CGP (10 nM) co-treatment.Norepinephrine (NE) increases cAMP as expected in iWA, and CGP does not alter this effectNorepinephrine (NE) is also known to induce lipolysis, and liberated fatty acids are required to functionally activate UCP1 protein and to stimulate heat production. CREB phosphorylation at Ser133 is increased after Norepinephrine (NE) treatment and significantly attenuated with CGP co-treatment in mouse iWA[3]. | ||||||||||||||||
Clinical Trial | |||||||||||||||||
分子量 | 337.28 | ||||||||||||||||
性状 | Solid | ||||||||||||||||
Formula | C12H19NO10 | ||||||||||||||||
CAS 号 | 108341-18-0 | ||||||||||||||||
中文名称 | 酒石酸去甲肾上腺素 | ||||||||||||||||
结构分类 |
| ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 | 4°C, protect from light, stored under nitrogen *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen) | ||||||||||||||||
溶解性数据 | In Vitro: H2O : 50 mg/mL(148.24 mM;Need ultrasonic) DMSO : ≥ 30 mg/mL(88.95 mM) *"≥" means soluble, but saturation unknown. 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
|